These findings implicate that the IL-6/STAT3/Jagged-1/Notch axis may be a useful target and combination of the STAT3 or Notch inhibitors with trastuzumab may prevent or delay clinical resistance and improve the efficacy of trastuzumab in gastric cancer. Here, IL6 is linked to gastric cancer.